C4 Therapeutics, Inc. Other Current Liabilities
C4 Therapeutics, Inc. (CCCC) had Other Current Liabilities of $995.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Other Liabilities, Current $995.00K.
- 2026-03-31: Other Liabilities, Current $1.57M.
- 2025-12-31: Other Liabilities, Current $1.40M.
- 2025-09-30: Other Liabilities, Current $1.75M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $995.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.40M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.58M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.88M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $1.87M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.82M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $2.29M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.14M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $2.04M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $2.11M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.46M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.26M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $3.11M 10-K · filed 2024-02-22 | $2.05M 10-K · filed 2023-02-23 |
| 2022-09-30 | $1.21M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $1.28M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $309.00K 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $413.00K 10-K · filed 2023-02-23 | |
| 2021-09-30 | $201.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $243.00K 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $887.00K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $469.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $164.00K 10-Q · filed 2020-11-12 | |
| 2019-12-31 | $280.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |